- Median progression-free survival (PFS) was 9.2 months in the PAG arm versus 6.0 months in the AG arm, hazard ratio (HR) with a 95 percent confidence interval (CI): 0.46 (0.15, 1.40);
- Overall response rate (ORR) of 50 percent, including one complete response in the PAG arm versus 33 percent and all partial responses in the AG arm;
- Median duration of response (DoR) of 8.1 months in the PAG arm versus 3.7 months in the AG arm;
- The exploratory analysis of median overall survival (OS) was similar between the treatment arms -- 11.8 months vs. 10.9 months in the PAG vs. AG arms respectively. Factors potentially having an impact on these results include less aggressive disease among patients in the AG arm and a greater than 40 percent discontinuation rate of PEGPH20 treatment at the time of the clinical hold, resulting in all patients receiving AG alone in both arms;
- The rate of thromboembolic (TE) events reduced from 43 percent to 9 percent in the PAG arm and from 25 percent to 6 percent in the AG arm with the introduction of prophylaxis with low molecular weight heparin (enoxaparin) from Stage One to Stage Two of the study.
Slingshot members are tracking this event:
Halozyme Presents Stage One Efficacy And Safety Analysis Of Phase 2 Clinical Study In Metastatic Pancreatic Cancer Patients Treated With PEGPH20
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|HALO||Community voting in process|
Slingshot Insights Explained
Jun 04, 2016
- Evaluating the Phase 2 data on PEGPH20 in Advanced Pancreatic Cancer HALO Executed On: Mar 09, 2017 at 01:00 PM EST
Related Keywords Pegph20, Metastatic Pancreatic Cancer, Phase 3 Halo 301 Clinical Study, Halo 109-202, Nab-paclitaxel, Abraxane, Gemcitabine, Pag Arm